This study examined the associations of polysubstance use, mood disorders, and chronic conditions with the history of anxiety disorder among patients with opioid use disorder (OUD). We performed a secondary analysis of the baseline data from a clinical trial including 1,645 individuals with OUD, of which 513 had anxiety disorder. Substance use disorders (SUDs) included alcohol, amphetamines, cannabis, cocaine, and sedative use disorders. Mood disorders included major depressive disorder (MDD) and bipolar disorder (BD). Chronic conditions were allergies, gastrointestinal problem(s), skin problem(s), and hypertension. Sedative use disorder, MDD, BD, skin problems, and hypertension were significantly associated with anxiety disorder (p < 0.05). Additionally, more than two SUDs, two mood disorders, and more than two chronic conditions were significantly associated with anxiety disorder (p < 0.05). These findings highlight the comorbid mental health and physical health problems in individuals with OUD, as well as the need for integrated multidisciplinary treatment plans.
AggarwalV.KosianS. (2011, September11–14). Feature selection and dimension reduction techniques in SAS. SAS Conference Proceedings. Portland, ME, United States. https://www.lexjansen.com/nesug/nesug11/sa/sa08.pdf.
2.
AltemusM.SarvaiyaN.Neill EppersonC. (2014). Sex differences in anxiety and depression clinical perspectives. Frontiers in Neuroendocrinology, 35(3), 320–330. https://doi.org/10.1016/j.yfrne.2014.05.004.
3.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). American Psychiatric Association.
4.
BatailleV.LensM.SpectorT. D. (2012). The use of the twin model to investigate the genetics and epigenetics of skin diseases with genomic, transcriptomic and methylation data. Journal of the European Academy of Dermatology and Venereology, 26(9), 1067–1073. https://doi.org/10.1111/j.1468-3083.2011.04444.x.
5.
BlancoC.VolkowN. D. (2019). Management of opioid use disorder in the USA: Present status and future directions. Lancet, 393(10182), 1760–1772. https://doi.org/10.1016/S0140-6736(18)33078-2
BrummettC. M.WaljeeJ. F.GoeslingJ.MoserS.LinP.EnglesbeM. J.BohnertA. S. B.KheterpalS.NallamothuB. K. (2017). New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surgery, 152(6), e170504. https://doi.org/10.1001/jamasurg.2017.0504.
8.
Bulut ÇakmakB.ÖzkulaG.IşıklıS.Özkan Göncüoğluİ.ÖcalS.AltınözA.E.TaşkıntunaN. (2018). Anxiety, depression, and anger in functional gastrointestinal disorders: A cross-sectional observational study. Psychiatry Research, 268, 368–372. https://doi.org/10.1016/j.psychres.2018.06.046.
9.
CarmiolN.PeraltaJ. M.AlmasyL.ContrerasJ.PachecoA.EscamillaM. A.KnowlesE. E.RaventósH.GlahnD. C. (2014). Shared genetic factors influence risk for bipolar disorder and alcohol use disorders. European Psychiatry, 29(5), 282–287. https://doi.org/10.1016/j.eurpsy.2013.10.001
10.
CarterC. A.Frischmeyer-GuerrerioP. A. (2018). The genetics of food allergy. Current Allergy and Asthma Reports, 18(1), 2. https://doi.org/10.1007/s11882-018-0756-z.
11.
ClarkeD. M.CurrieK. C. (2009). Depression, anxiety and their relationship with chronic conditions: A review of the epidemiology, risk and treatment evidence. Medical Journal of Australia, 190, S54–S60. https://doi.org/10.5694/j.1326-5377.2009.tb02471.x.
12.
ConnorJ. P.GulloM. J.WhiteA.KellyA. B. (2014). Polysubstance use: Diagnostic challenges, patterns of use and health. Current Opinion in Psychiatry, 27(4), 269–275. https://doi.org/10.1097/YCO.0000000000000069.
13.
CrowleyD.M.JonesD.E.CoffmanD.L.GreenbergM.T. (2014). Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial. Preventive Medicine, 62, 71–77. https://doi.org/10.1016/j.ypmed.2014.01.029.
14.
DegenhardtL.HallW. (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet, 379, 55–70. https://doi.org/10.1016/S0140-6736(11)61138-0.
15.
DegenhardtL.CharlsonF.MathersB.HallW.D.FlaxmanA.D.JohnsN.VosT. (2014). The global epidemiology and burden of opioid dependence: Results from the global burden of disease 2010 study. Addiction, 109, 1320–1333. https://doi.org/10.1111/add.12551.
16.
DegenhardtL.StockingsE.StrangJ.MarsdenJ.HallW.D. (2016). Illicit drug dependence. In PatelV.ChisholmD.DuaT.LaxminarayanR.Medina-MoraM.VosT. (Eds.), Disease control priorities, (volume 4): Mental, neurological, and substance use disorders (3rd ed., pp. 109–126). World Bank.
17.
de LorentL.AgorastosA.YassouridisA.KellnerM.MuhtzC. (2016). Auricular acupuncture versus progressive muscle relaxation in patients with anxiety disorders or major depressive disorder: A prospective parallel group clinical trial. Journal of Acupuncture and Meridian Studies, 9(4), 191–199. https://doi.org/10.1016/j.jams.2016.03.008.
18.
EbertB.WaffordK. A.DeaconS. (2006). Treating insomnia: Current and investigational pharmacological approaches. Pharmacology and Therapeutics, 112, 612–629. https://doi.org/10.1016/j.pharmthera.2005.04.014
19.
FaulF.ErdfelderE.BuchnerA.LangA. G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 41, 1149–1160. https://doi.org/10.3758/BRM.41.4.1149.
20.
FerrariA. J.CharlsonF. J.NormanR.FlaxmanA. D.PattenS. B.VosT.WhitefordH. A. (2013). The epidemiological modelling of major depressive disorder: Application for global burden of disease 2010 study. PLoS One, 8(7), e69637. https://doi.org/10.1371/journal.pone.0069637.
21.
FlorenceC. S.ZhouC.LuoF.XuL. (2016). The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Medical Care, 54(10), 901–906. https://doi.org/10.1097/MLR.0000000000000625.
22.
GargR.Fulton-KehoeD.FranklinG.2017. Patterns of opioid use and risk of opioid overdose death among Medicaid patients. Medical Care, 55, 669–676. https://doi.org/10.1097/MLR.0000000000000738.
23.
GoodwinR. D.RodginS.GoldmanR.RodriguezJ.deVosG.SerebriskyD.FeldmanJ. M. (2017). Food allergy and anxiety and depression among ethnic minority children and their caregivers. The Journal of Pediatrics, 187, 258–264. https://doi.org/10.1016/j.jpeds.2017.04.055
24.
GuffantiG.GameroffM. J.WarnerV.TalatiA.GlattC. E.WickramaratneP.WeissmanM. M. (2016). Heritability of major depressive and comorbid anxiety disorders in multi-generational families at high risk for depression. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 171(8), 1072–1079. https://doi.org/10.1002/ajmg.b.32477
25.
HaninG.Shenhar-TsarfatyS.YayonN.YauY. H.BennettE. R.SklanE. H.RaoD. C.RankinenT.BouchardC.Geifman-ShochatS.ShifmanS.GreenbergD. S.SoreqH. (2014). Competing targets of microRNA-608 affect anxiety and hypertension. Human Molecular Genetics, 23(17), 4569–4580. https://doi.org/10.1093/hmg/ddu170.
26.
HayleyA. C.StoughC.DowneyL. A. (2017). DSM-5 cannabis use disorder, substance use and DSM-5 specific substance-use disorders: Evaluating comorbidity in a population-based sample. European Neuropsychopharmacology, 27(8), 732–743. https://doi.org/10.1016/j.euroneuro.2017.06.004.
27.
HsiangW. R.McGeochC.LeeS.CheungW.BecherR.DavisK. A.SchusterK. (2019). Opioid dependency is independently associated with inferior. Injury, 50(1), 192–196. https://doi.org/10.1016/j.injury.2018.10.015.
28.
HsuD. J.McCarthyE. P.StevensJ. P.MukamalK. J. (2017). Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001–12. Addiction, 112, 1558–1564. https://doi.org/10.1111/add.13795.
29.
HughesK.BellisM. A.HardcastleK. A.SethiD.ButchartA.MiktonC.JonesL.DunneM. P. (2017). The effect of multiple adverse childhood experiences on health: A systematic review and meta-analysis. Lancet Public Health, 2(8), e356–e366. https://doi.org/10.1016/S2468-2667(17)30118-4.
30.
IyiewuareP. O.McCulloughC.OberA.BeckerK.OsillaK.WatkinsK. E. (2017). Demographic and mental health characteristics of individuals who present to community health clinics with substance misuse. Health Services Research and Managerial Epidemiology, 4, 2333392817734523. https://doi.org/10.1177/2333392817734523.
31.
JohnsonH. M. (2019). Anxiety and hypertension: Is there a link? A literature review of the comorbidity relationship between anxiety and hypertension. Current Hypertension Reports, 21(9), 66. https://doi.org/10.1007/s11906-019-0972-5.
32.
KaramchandaniK.CarrZ.J.BonaviaA.TungA. (2018). Critical care pain management in patients affected by the opioid epidemic: A review. Annals of the American Thoracic Society, 15(9), 1016–1023. https://doi.org/10.1513/AnnalsATS.201801-028FR.
33.
KarilaL.RouxP.RollandB.BenyaminaA.ReynaudM.AubinH. J.LançonC. (2014). Acute and long-term effects of cannabis use: A review. Current Pharmaceutical Design, 20, 4112–4118. https://doi.org/10.2174/13816128113199990620.
34.
KendlerK. S.JacobsonK. C.PrescottC. A.NealeM. C. (2003). Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. The American Journal of Psychiatry, 160, 687–695. https://doi.org/10.1176/appi.ajp.160.4.687.
35.
KesslerR. C.ChiuW. T.DemlerO.WaltersE. E. (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 62(6), 617–627. https://doi.org/10.1001/archpsyc.62.6.617.
36.
KokuboY.PadmanabhanS.IwashimaY.YamagishiK.GotoA. (2019). Gene and environmental interactions according to the components of lifestyle modifications in hypertension guidelines. Environmental Health and Preventive Medicine, 24(1), 19. https://doi.org/10.1186/s12199-019-0771-2.
37.
LangdonK. J.DoveK.RamseyS. (2019). Comorbidity of opioid-related and anxiety-related symptoms and disorders. Current Opinion in Psychology, 30, 17–23. https://doi.org/10.1016/j.copsyc.2018.12.020.
38.
LeeS. Y.PoonW. Y.BentlerP. M. (1995). Two-stage estimation of structural equation models with continuous and polytomous variables. The British Journal of Mathematical and Statistical Psychology, 48, 339–358. https://doi.org/10.1111/j.2044-8317.1995.tb01067.x.
39.
LiuF.CuiJ.LiuX.ChenK. W.ChenX.LiR. (2020). The effect of tai chi and Qigong exercise on depression and anxiety of individuals with substance use disorders: A systematic review and meta-analysis. BMC Complementary Medicine and Therapies, 20(1), 161. https://doi-org.wvu.idm.oclc.org/10.1186/s12906-020-02967-8.
40.
ManzoniA. P.WeberM. B.NagatomiA. R.PereiraR. L.TownsendR. Z.CestariT. F. (2013). Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. Anais Brasileiros de Dermatologia, 88(6), 894–899. https://doi.org/10.1590/abd1806-4841.20131915.
41.
MarquesA. A.BevilaquaM. C.da FonsecaA. M.NardiA. E.ThuretS.DiasG. P. (2016). Gender differences in the neurobiology of anxiety: Focus on adult hippocampal neurogenesis. Neural Plasticity, 2016, 5026713. https://doi.org/10.1155/2016/5026713.
42.
McHughR. K. (2015). Treatment of co-occurring anxiety disorders and substance use disorders. Harvard Review of Psychiatry, 23(2), 99.
43.
McHughR. K.VotawV. R.BarlowD. H.FitzmauriceG. M.GreenfieldS. F.WeissR. D. (2017). Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods. Contemporary Clinical Trials, 60, 105–112. https://doi.org/10.1016/j.cct.2017.07.006.
44.
MidenfjordI.PolsterA.SjövallH.TörnblomH.SimrénM. (2019). Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. Neurogastroenterology and Motility, 31(8), 1–14. https://doi.org/10.1111/nmo.13619.
45.
NelsonB. D. (2001, April22–25). Variable reduction for modeling using PROC VARCLUS. SAS Conference Proceedings: SAS Users Group International Conference, 2001, Long Brach, CA, United States. http://www2.sas.com/proceedings/sugi26/p261-26.pdf.
46.
OlveraR. L.BeardenC. E.VelliganD. I.AlmasyL.CarlessM. A.CurranJ. E.WilliamsonD. E.DuggiralaR.BlangeroJ.GlahnD. C. (2011). Common genetic influences on depression, alcohol, and substance use disorders in Mexican-American families. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 156B(5), 561–568. https://doi.org/10.1002/ajmg.b.31196.
47.
OnyekaI. N.Collier HøeghM.Nåheim EienM.Cand.MagNwaruB. I.MelleI. (2019). Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: A systematic review and meta-analysis. Journal of Dual Diagnosis, 15(3), 192–206. https://doi.org/10.1080/15504263.2019.1619007.
48.
PianeG. M.SmithT. C. (2014). Building an evidence base for the co-occurrence of chronic disease and psychiatric distress and impairment. Preventing Chronic Disease, 11, 140211. https://doi.org/10.5888/pcd11.140211.
49.
PlayerM. S.PetersonL. E. (2011). Anxiety disorders, hypertension, and cardiovascular risk: A review. The International Journal of Psychiatry in Medicine, 41(4), 365–377.
50.
PotterJ. S.MarinoE. N.HillhouseM. P.NielsenS.WiestK.CanamarC. P.MartinJ. A.AngA.BakerR.SaxonA. J.LingW. (2013). Buprenorphine/naloxone and methadone maintenance treatment outcomes for the opioid analgesic, heroin and combined users: Findings from starting treatment with agnostic replacement therapies (START). Journal of Studies on Alcohol and Drugs, 74, 605–613. https://doi.org/10.15288/jsad.2013.74.605.
51.
ReinholdJ. A.RickelsK. (2015). Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert opinion on pharmacotherapy, 16(11), 1668–1669. https://pubmed.ncbi.nlm.nih.gov/26159446/
52.
RiggK. K.McLeanK.MonnatS. M.SternerG. G.IIIVerderyA. M. (2019). Opioid misuse initiation: Implications for intervention. Journal of Addictive Diseases, 37(3–4), 111–122. https://doi.org/10.1080/10550887.2019.1609336.
53.
RønnstadA. T. M.Halling-OvergaardA. S.HamannC. R.SkovL.EgebergA.ThyssenJ. P. (2018). Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 79(3), 448–456. https://doi.org/10.1016/j.jaad.2018.03.017
54.
SaxonA. J.LingW.HillhouseM.ThomasC.HassonA.AngA.JacobsP. (2013). Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence, 128, 71–76. https://doi.org/10.1016/j.drugalcdep.2012.08.002.
55.
ShakerM. S.SchwartzJ.FergusonM. (2017). An update on the impact of food allergy on anxiety and quality of life. Current Opinion in Pediatrics, 29(4), 497–502. https://doi.org/10.1097/MOP.0000000000000509.
56.
SpothR.TrudeauL.ShinC.RalstonE.RedmondC.GreenbergM.FeinbergM. (2013). Longitudinal effects of universal preventive intervention on prescription drug misuse: Three randomized controlled trials with late adolescents and young adults. American Journal of Public Health, 103(4), 665–672. https://doi.org/10.2105/AJPH.2012.301209.
57.
StoiceaN.CostaA.PerielL.UribeA.WeaverT.BergeseS. D. (2019). Current perspectives on the opioid crisis in the US healthcare system: A comprehensive literature review. Medicine (Baltimore), 98(20), e15425. https://doi.org/10.1097/MD.0000000000015425.
58.
StonerockG. L.HoffmanB. M.SmithP. J.BlumenthalJ. A. (2015). Exercise as treatment for anxiety: Systematic review and analysis. Annals of Behavioral Medicine, 49(4), 542–556. https://doi.org/10.1007/s12160-014-9685-9.
59.
TsuangM. T.BarJ. L.HarleyR. M.LyonsM. J. (2001). The Harvard twin study of substance abuse: What we have learned. Harvard Review of Psychiatry, 9(6), 267–279.
60.
VancampfortD.KoyanagiA.HallgrenM.ProbstM.StubbsB. (2017). The relationship between chronic physical conditions, multimorbidity and anxiety in the general population: A global perspective across 42 countries. General Hospital Psychiatry, 45, 1–6. https://doi.org/10.1016/j.genhosppsych.2016.11.002.
61.
Van KaneganG.WorleyJ. (2018). Complementary alternative and integrative treatment for substance use disorders. Journal of Psychosocial Nursing and Mental Health Services, 56(6), 16–21. https://doi-org.wvu.idm.oclc.org/10.3928/02793695-20180521-04.
62.
VorspanF.MehtelliW.DupuyG.BlochV.LépineJ. P. (2015). Anxiety and substance use disorders: Co-occurrence and clinical issues. Current Psychiatry Reports, 17(2), 4. https://doi.org/10.1007/s11920-014-0544-y.
WuL. T.ZhuH.GhitzaU. E. (2018). Multicomorbidity of chronic diseases and substance use disorders and their association with hospitalization: Results from electronic health records data. Drug and Alcohol Dependence, 192, 316–323. https://doi.org/10.1016/j.drugalcdep.2018.08.013.
